Please Note: This trial is no longer enrolling new participants
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer
| Protocol No. | CTO-CP-MVC-101-01 | Scope | National |
|---|---|---|---|
| Principal Investigator | Anita Turk | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase I/II |
